<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671265</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1210-CRT-ESC-IIT</org_study_id>
    <nct_id>NCT03671265</nct_id>
  </id_info>
  <brief_title>Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC</brief_title>
  <official_title>A Single Arm Exploratory Study of Chemotherapy Plus Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Locally Advanced Esophageal Squamous Cell Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is an openlabel，single center
      ，non-randomized ，Single Arm Exploratory Study . This clinical study is an
      investigator-initiated clinical trial（IIT). The objective of this study is to evaluate the
      efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 and
      chemotherapy in patients with Locally Advanced Esophageal Squamous Cell Carcinomas。
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AE), Serious Adverse Event(SAE) Adverse events</measure>
    <time_frame>Through study completion, an average of half a year]</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>1year and 3years</time_frame>
    <description>Progression-Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>1year and 3years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>SHR-1210 + Chemotherapy + Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy(IMRT or VMAT): 95%PTV 54Gy/30 fraction,95%PTV 60Gy/30 fraction ,5 fractions per week, for 6 weeks. Radiation begun the day on which first dose of SHR-1210.
SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.
Chemotherapy: Docetaxel 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22, total 4 cycles; Cisplatin 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22;, total 4 cycles.
Apatinib: 250mg/d，PO Qd(4 weeks after Radiotherapy, until the end of 8th ycle )</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1210</intervention_name>
    <description>SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.</description>
    <arm_group_label>SHR-1210 + Chemotherapy + Radiotherapy</arm_group_label>
    <other_name>Anti-PD-1 Antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT or VMAT</intervention_name>
    <description>The IMRT or VMAT technique was used in our study.</description>
    <arm_group_label>SHR-1210 + Chemotherapy + Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2.</description>
    <arm_group_label>SHR-1210 + Chemotherapy + Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age:18-75 years, male or female.

          2. Histologically confirmed primary Squamous Cell Carcinoma of the Esophagus,Local
             advanced esophageal cancer diagnosed by pathology and imaging,clinical stage T3-4N0M0,
             T1-4N+M0,Ⅱ-Ⅳa.

          3. Pre-treatment evaluation can not tolerate concurrent radiochemotherapy or rejection of
             the concurrent use of chemotherapy with radiotherapy.

          4. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.

          5. ECOG 0-1.

          6. Adequate organ function.

          7. Life expectancy of greater than 6 months.

          8. Patient has given written informed consent.

        Exclusion Criteria:

          1. Patients who have or are currently undergoing additional chemotherapy, radiation
             therapy, targeted therapy or immunotherapy.

          2. Known history of hypersensitivity to macromolecular protein preparation or any
             components of the SHR- 1210 formulation.

          3. Subjects before or at the same time with other malignant tumors (except which has
             cured skin basal cell carcinoma and cervical carcinoma in situ);

          4. Subjects with any active autoimmune disease or history of autoimmune disease

             - Page 4 of 4 [DRAFT] -

          5. Uncontrolled clinically significant heart disease, including but not limited to the
             following: (1) &gt; NYHA II congestive heart failure; (2) unstable angina, (3) myocardial
             infarction within the past 1 year; (4) clinically significant supraventricular
             arrhythmia or ventricular arrhythmia requirement for treatment or intervention;

          6. Active infection or an unexplained fever &gt; 38.5°C during screening or before the first
             scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion
             of the investigator);

          7. Received a live vaccine within 4 weeks of the first dose of study medication.

          8. Pregnancy or breast feeding.

          9. Decision of unsuitableness by principal investigator or physician-incharge.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Tianjin Medical University Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Wang, M. D.</last_name>
      <phone>08623340123-1121</phone>
      <email>wangping@tjmuch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 2, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>January 7, 2019</last_update_submitted>
  <last_update_submitted_qc>January 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Concurrent chemoradiation</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>SHR-1210</keyword>
  <keyword>Apatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

